We looked inside some of the tweets by @PamBelluck and found useful information for you.
Inside 100 Tweets
92% of retweets are based on interesting content.
The new Alzheimer’s drug should only be used for a much narrower group of patients than the F.D.A.’s label allows, experts said. Even a strong supporter of approval said “there’s no evidence that it could be beneficial for any other stage of Alzheimer’s.” https://t.co/sp65vv5Lp7
Post-covid patients may experience new medical problems Analysis of almost 2m #patients found issues for nearly 25% them — including those who had a mild or asymptomatic #infection cc ➤ @RWalensky @VirusesImmunity @PaulSaxMD https://t.co/cBqPwE6hyH ht @PamBelluck @nytimes https://t.co/Ydynkb2G8Y
Still, it seems to be the largest so far looking at post-Covid health issues. It underscores, says @zalaly, that "people with long Covid need multidisciplinary care and our health systems should adapt to this reality and develop capacity to deal with these patients."3/3
The study has limitations, including: it only uses private health insurance records, no control group to allow comparison to people who didn't have Covid, no data on when symptoms arose or how long problems persisted, diagnostic codes can miss or miscategorize symptoms. 2/3
Thank you so much! I really appreciate this very kind comment! https://t.co/Umvh0DhLhb
what a public service it was and still is incredibly proud of this newsroom https://t.co/vGKIvlGtdg
This week, the FDA approved the new Alzheimer's drug aducanumab, but it’s unclear if the costly treatment actually leads to improved cognition and memory in people with the disease. @NYtimes's reporter @PamBelluck shares more on #SciFriLive📻. https://t.co/v8ILc5Er9x